India has finally granted emergency use approval for Zydus Cadila’s COVID-19 vaccine. This will be world’s first DNA shot against the coronavirus, in adults and children aged 12 years and above.
This vaccine approval gives a boost to India’s vaccination programme. India aims to inoculate all eligible adults by December 2021. Moreover, it will provide the first shot for those under 18, as the country still struggles to contain the virus spread in some states.
The vaccine, ZyCoV-D, uses a section of genetic material from the virus that gives instructions as either DNA or RNA to make the specific protein that the immune system recognises and responds to.
Zydus Cadila’s vaccine which was developed in partnership with the Department of Biotechnology, is the second home-grown shot to get emergency authorization in India after Covaxin.
The company’s vaccine which was developed in partnership with the Department of Biotechnology, is the second home-grown shot to get emergency authorization in India after Covaxin.
Zydus Cadila had submitted data evaluating a two-dose regimen for the shot in July. It now plans to seek regulatory approval for the same.
It had also applied for the authorization of ZyCoV-D on July 1. This was based on an efficacy rate of 66.6% in a late-stage trial of over 28,000 volunteers nationwide.
India had experienced a deadly second wave during the May-June period. Many people lost their lives and now when it comes to the third wave, doctors say, it depends on people and their awareness levels.
No one can deny the importance of following Covid-appropriate behaviour. In a big breather for the entire country, AIIMS director Randeep Guleria asserted that India might not see the third wave of coronavirus.
ALSO READ | Natural Immunity Versus Vaccine-Induced Immunity: Which One Protects The Most?